This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Bristol-Myers Squibb faces new antitrust complaint over Thalomid, Revlimid

( July 16, 2021, 22:31 GMT | Official Statement) -- MLex Summary: Molina Healthcare filed a complaint accusing Celgene and its owner, Bristol-Myers Squibb, of illegally monopolizing the market for Thalomid and Revlimid. The complaint claims that Celgene has successfully interfered with competitors’ efforts to develop and/or obtain approval from the US Food and Drug Administration for generic versions of drugs at each progressive step of development. Molina also says Celgene entered into illegal pay-for-delay agreements where it could not stop potential generics at the FDA.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections